Abstract

ObjectiveParkinson’s disease (PD) is the second most prevalent neurodegenerative disease after Alzheimer's disease (AD) worldwide. The prevalence of small intestinal bacterial overgrowth (SIBO) in PD patients is high. We conducted this comprehensive systematic review and meta-analysis to determine the association between SIBO and PD.MethodsA comprehensive literature search of the PubMed, Cochrane Library and EMBASE databases was performed to identify studies correlating SIBO with PD. Studies were screened, and relevant data were extracted and analysed. We calculated the pooled prevalence of SIBO in all individuals with PD and compared the prevalence of SIBO between the two groups to calculate an odds ratio (OR) and 95% confidence interval (CI). Egger’s test was performed to assess publication bias.ResultsEleven studies with 973 participants met the inclusion criteria. The pooled prevalence of SIBO in patients with PD was 46% (95% CI 36–56). A random-effects model was applied given the heterogeneity (I2 = 83%) detected among the studies. Egger’s test indicated no publication bias (p = 0.0657). Subgroup analyses showed that the prevalence of SIBO was greater in studies including patients diagnosed using the lactulose hydrogen breath test (LBT) (51%, 95% CI 37–65) than in those including patients diagnosed using the glucose hydrogen breath test (GBT) (35%, 95% CI 20–50), and the prevalence of SIBO in PD was highest (55%, 95% CI 38–72) in patients diagnosed by the LBT and GBT. The prevalence of SIBO was 52% (95% CI 40–64) among patients from Western countries and 33% (95% CI 22–43) among patients from Eastern countries. The pooled OR of SIBO in PD patients compared with healthy controls was 5.22 (95% CI 3.33–8.19, p < 0.00001). We did not identify an obvious predictor of SIBO in PD patients.ConclusionIn conclusion, our meta-analysis found a strong association between SIBO and PD with approximately half of PD patients testing positive for SIBO. These relationships significantly differed based on diagnostic test and geographic area.

Highlights

  • Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease after Alzheimer’s disease (AD) worldwide

  • We conducted this comprehensive systematic review and meta-analysis to determine the association between PD and Small intestinal bacterial overgrowth (SIBO)

  • Study selection Studies were included if they met the following criteria: (a) studies that had a cross-sectional, cohort or case– control design; (b) studies that recruited subjects who met the PD diagnostic criteria; (c) studies in which SIBO was diagnosed with the following tests: the glucose hydrogen breath test (GBT), lactulose hydrogen breath test (LBT) or jejunal aspirate culture (JAC); (d) studies that compared the association of PD and SIBO; and (e) studies with full texts available

Read more

Summary

Introduction

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease after Alzheimer’s disease (AD) worldwide. PD affects the nerves of the entire gastrointestinal (GI) tract, and most PD patients experience abnormal gastrointestinal motility and delayed gastric emptying. Recent research has shown changes in the intestinal microbiota of PD patients, which is associated with the clinical phenotype of PD [4]. The gold standard for diagnosing SIBO is a microbial investigation of jejunal aspirate culture (JAC). Current studies do not provide explicit evidence to confirm the correlation at home and abroad. We conducted this comprehensive systematic review and meta-analysis to determine the association between PD and SIBO

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call